参考文献
1 Zacks DN，Ezra E，Terada Y，et al．Verteporfin photodynamic therapy in the rat model of choroidal neovascularization：angiographic and histologic characterization．Invest Ophthalmol Vis Sci，2002，43：2384—2391
2 Yano K，Brown LF，Detmar M．Control of hair growth and follicle size by VEGF－mediated angiogenesis．J Clin Invest，2001，107：409—417
3 Ishida S，Shinoda K，Kawashima S，et al．Coexpression of VEGF receptors VEGF－R2and neuropilin－1in proliferative diabetic retinopathy．Invest Ophthalmol Vis Sci，2000，41：1649—1656
4 Ishihama H，Ohbayashi M，Kurosawa N，et al．Colocalization of neuropilin－1and flk－1in retinal neovascularizationin a mouse model of retinopathy．Invest Ophthalmol Vis Sci，2001，42：1172—1178
5 Sone H，Deo BK，Kumagai AK．Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells．Invest Ophthalmol Vis Sci，2000，41：1876—1884
6 Peczynska J，Urban M，Glowinska B，et al．Growth hormone，insulin－like growth factor and insulin－like growth factor binding protein in young typeⅠdiabetes patients with the onset of diabetic angiopathy．Pol Merkuriusz Lek，2003，14：336—339
7 Feldmann B，Jehle PM，Mohan S，et al．Diabetic retinopathy is associated with decreased serum levels of free IGF－Ⅰand changes of IGF－binding proteins．Growth Horm IGF Res，2000，10：53—59
8 Wacharasindhu S，Srivuthana S，Aroonparkmongkol S．Insulin－like growth factors and their binding proteins in children with IDDM．J Med Assoc Thai，2002，85：41—52
9 Chantelau E，Meyer－Schwickerath R．Reversion of‘early worsening’of diabetic retinopathy by deliberate restoration of poor metabolic control．Ophthalmologica，2003，20：269—276
10 Frystyk J，Bek T，Flyybjerg A，et al．The relationship between the circulating IGF system and the presence of retinopathy in typeⅠdiabetic patients．Diabet Med，2003，20：269—276
11 Burgos R，Mateo C，Canton A，et al．Vitreous levels of IGF－Ⅰ，IGF binding protein 1，and IGF binding protein 3in proliferative diabetic retinopathy：a case－control study．Diabetes Care，2000，23：80—83
12 Simo R，Lecube A，Segura RM，et al．Free insulin growth factor－Ⅰand vascular endothelial groth factor in the vitreous fluid of patients with proliferative diabetic retinopathy．Am J Ophthalmol，2002，134：376—382
13 DeBosch BJ，Baur E，Deo BK，et al．Effects of insulin－like growth factor－Ⅰon retinal endothelial cell glucose transport and proliferation．J Neurochem，2001，77：1157—1167
14 Spraul CW，Kaven C，Amann J，et al．Effect of insulin－like growth factors 1and 2，and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro．Ophthalmic Res，2000，32：244—248
15 Wilson SH，Davis MI，Caballero S，et al．Modulation of retinal endothelial cell behaviour by insulin－like growth factorⅠand somatostatin analogues：implications of diabetic retinopathy．Growth Horm IGF res， 2001，11（suppl A）：53—59
16 Tatsuya K，David V，Kiyoshi S，et al．Knockout of insulin and IGF－1receptors on vascular endothelial cells protects against retinal neovascularization．J Clin Invest，2003，111：1835—1842
17 Keiji S，Walker H，Busby J et al．Tissue transglutaminase facilitates the polymerization of insulin－like growth factor－binding protein－1（IGFBP－1）and leads to loss of IGFBP－1’ability to inhibit insulin－like growth factor－1－stimulated protein synthesis．J Biol Chem，2001，276：8740—8745
18 Giannini S，Cresci B，Pala L，et al．IGFBPs modulate IGF－Ⅰand high glucose－controlled growth of human retinal endothelial cells．J Endocrinal，2001，171：273—284
19 Davis MI，Wilson SH，Grant MB，et al．The therapeutic problem of proliferative diabetic retinopathy：targeting somatostatin receptors．Horm Metab Res，2001，33：295—299
20 Growth Hormone Antagonist for Proliferative diabetic retinopathy study group．The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy．Ophthalmology，2001，108：2266—2272
21 Thrailkill KM．insulin－like growth factor－Ⅰin diabetes mellitus：its physiology，metabolic effects，and potential clinical utility．Diabetes Technol Ther，2000，2：69—80
22 Holt RI，Simpson HL，Sonksen PH．The role of the growth hormoneinsulin－like growth factor axis in glucose homeostasis．Diabet Med，2003，20：3—15
23 Sarah KB，Chad ENR，Thomas WG．An eye on insulin．J Clin Invest，2003，111：1817—1819
24 Chang LK，Garcia－Cardena G，Farnebo F，et al．Dose－dependent response of FGF－2for lymphangiogenesis．Proc Natl Acad Sci USA，2004，101（32）：11658—11663
25 Yoshida S，Yoshida A，Ishibashi T．Induction of IL－8，MCP－1，and bFGF by TNF－alpha in retinal glial cells：implications for retinal neovascularization during post－ischemic inflammation．Graefes Arch Clin Exp Oph－thalmol，2004，242（5）：409—413
26 Yoshida S，Yoshida A，Matsui H，et al．Involvement of macrophage chemotactic protein－1and interleukin－1beta during inflammatory but not basic fibroblast growth factor－dependent neovascularization in the mouse cornea．Lab Invest，2003，83（7）：927—938
27 Tsutsumi C，Sonoda KH，Egashira K，et al．The critical role of ocularinfiltrating macrophages in the development of choroidal neovascularization．J Leukoc Biol，2003，74（1）：25—32
28 Klenkler B，Sheardown H．Growth factors in the anterior segment：role in tissue maintenance，wound healing and ocular pathology．Exp Eye Res，2004，79（5）：677—688
29 Hollborn M，Krausse C，Iandiev I，et al．Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease．Lab Invest，2004，84（8）：963—972
30 Nakabayashi M，Morishita R，Nakagami H，et al．HGF／NK4inhibited VEGF－induced angiogenesis in vitro cultured endothelial cells and in vivo rabbit model．Diabetologia，2003，46（1）：115—123
31 Umeda N，Ozaki H，Hayashi H，et al．Non－paralleled increase of hepatocyte growth factor and vascular endothelial growth factor in the eyes with angiogenic and nonangiogenic fibroproliferation．Ophthalmic Res，2002，34（1）：43—47
32 Xin X，Yang S，Ingle G，et al．Hepatocyte growth factor enhances vascular endothelial growth factor－induced angiogenesis in vitro and in vivo．Am J Pathol，2001，158（3）：1111—1120
33 Anitua E，Andia I，Sanchez M，et al．Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture．J Orthop Res，2005，23（2）：281—286
34 Rahman S，Patel Y，Murray J，et al．Novel hepatocyte growth factor（HGF）binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met－integrin induced signalling pathway in endotheli－al cells．BMC Cell Biol，2005，17；6（1）：8
35 Marui A，Kanematsu A，Yamahara K，et al．Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation．J Vasc Surg，2005，41（1）：82—90
36 Haraguchi M，Komuta K，Akashi A，et al．Elevated IL－8levels in the drainage vein of respectable Dukes’C colorectal cancer indicate high risk for developing hepatic metastasis．Oncol Rep，2002，9：159—165
37 Inoue K，Slaton JW，Eve BY，et al．Interleukin 8expression regulates tumorigenicity and metastases in androgen－independent prostate cancer．Clin Cancer Res，2000，6：2104—2119
38 Wierda WG，Johnson MM，Do KA，et al．Plasma interleukin 8level predicts for survival in chronic lymphocytic leukaemia．Br J Haematol，2003，120：452—456
39 Li A，Dubey S，Varney ML，et al．IL－8directly enhanced endothelial cell survival，proliferation，and matrix metalloproteinases production and regulated angiogenesis．J Immunol，2003，170：3369—3376
40 Inoue K，Slaton JW，Kim SJ，et al．Interleukin 8expression regulates tumorigenicity and metastasis in human bladder cancer．Cancer Res，2000，60：2290—2299
41 Yuuki T，Kanda T，Kimura Y，et al．Inflamatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy．J Diabetes Complications，2001，15：257—259
42 Doganay S，Evereklioglu C，Er H，et al，Comparison of serum NO，TNF－alpha，IL－1beta，sIL－2R，IL－6and IL－8levels with grades of retinopathy in patients with diabetes mellitus．Eye，2002，16：163—170
43 Mitamura Y，Harada T，Harada C，et al．NF－kappa B in epiretinal membranes after human diabetic retinopathy．Diabetologia，2003，46：699—703
44 Ward EG，Grosios K，Markham AF，et al．Genomic structures of the human angiopoietins show polymorphism in angiopoietin－2．Cytogenet Cell Genet，2001，94：147—154
45 Teichert－Kuliszewska，Maisonpierre PC，Jones N，et al．Biological action of angiopoietin－2in a fibrin matrix model of angiogenesis is associated with activation of Tie2．Cardivasc Res，2001，49：659—670
46 Shahrara S，Volin MV，Connors MA，et al．Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue．Arthritis Res，2002，4：201—208
47 Koch AE．The role of angiogenesis in rheumatoid arthritis：recent developments．Ann Rheum Dis，2000，59（suppl 1）：65—71
48 Kampfer H，Pfeilschifter J，Frank S．Expressional regulation of angiopoietin－1and－2and the tie－1and－2receptor tyrosine kinases during cutaneous wound healing：a comparative study of normal and impaired repair．Lab Invest，2001，81：361—373
49 Lin TN，Nian GM，Chen SF，et al．Induction of Tie－1and Tie－2receptor protein expression after cerebral ischemia－reperfusion．J Cereb Blood Flow Metab，2001，21：690—701
50 Urmbach JH，Hammerer P，Sevinc S，et al．The expression of angiopoietins and their receptor Tie－2in human prostate carcinoma．Anticancer Res，2000，20（6D）：5217—5220
51 Chan JL，Bluher S，Yiannakouris N，et al．Regulation of circulating soluble leptin receptor levels by gender，adiposity，sex steroids，and leptin observational and interventional studies in human．Diabetes，2002，51（7）：2105—2112
52 Asakawa H，Tokunaga K，Kawakami F．Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2diabetes mellitus patients．J Diabetes and Its Complications，2001，15：57—62
53 Correia MLG，Morgan DA，Sivitz WI，et al．leptin acts in the central nervous system to produce dose－dependent changes in arterial pressure．Hypertension，2001，37：936—942
54 Kou JJ，Jones OB，Hall JE．Inhibition of NO synthesis enhances chronic cardiovascular and renal action of leptin．Hypertension，2001，37：670—676
55 Winters B，Mo Z，Brooks－Asplund E，et al．Reduction of obesity，as induced by leptin，reverses endothelial dysfunction in obese（Lep（ob））mice．J Appl Physiol，2000，89：2382—2390
56 Quehenberger P，Exner M，Suinder－Plas smann R，et al．Leptin induces endothelin－1in endothelial cells in vitro．Circ Res，2002，90：711—718
57 Cao R，Brakenhielm E，Wahlested C，et al．Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF－2and VEGF．Proc Natl Acad Sci USA，2001，98：6390—6395
58 Park HY，Kwon HM，Lim HJ，et al．Potential role of leptin in angiogenesis：leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and vitro．Exp Mol med，2001，33：95—102
59 Ckaya G，Ozata M，Bauraktar Z，et al．Is leptin associated with diabetic retinopathy．Diabetes Care，2000，23：371—376
60 Goetze S，Bungenstock A，Czupalla C．Leptin induces endothelial cell migration through Akt，which is inhibited by PPAR gamma－ligands．Hypertension，2002，40：748—754
61 Cui ZJ，Dan H，Potter MJ，et al．The role of leptin in choroidal neovascularization．Am J Ophthalmol，2001，132：792—794
62 Gariano RF，Nath AK，Amico DJ，et al．Elevation of vitreous leptin in diabetic retinopathy and retinal detachment．Invest Ophthalmol Vis Sci，2000，41：3576—3581
63 Kazlauskas A．A new member of an old family．Nat Cell Biol．2000，2（5）：E78—79
64 Li X，Ponten A，Aase K，et al．PDGF－C is a new protease－activated ligand for the PDGF alpha－receptor．Nat Cell Biol，2000，2（5）：302—309
65 陈 瑛，栾黎明，杨增明．前列腺素核受体系统信号转导及基因表达调控．生物化学与生物物理进展，2004，31：209—212
66 邹 平，李著华．前列腺素E1及其临床应用研究进展．中国煤炭工业医学杂志，2003，6：1127—1128
67 王 毅，孙丰源．黏附分子与甲状腺相关眼病．眼科研究，2001，19： 87—90
68 Robert Visse，Hideaki Nagase．Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure，function，and biochemistry．Circ Res，2003，92：827—839
69 Fang J，Shing Y，Wiederschain D，et al．Matrixmetalloproteinase－2is required for the switch to the angiogenic phenotype in a tumor model．Proc Natl Acad Sci USA，2000，97（8）：3884—3889
70 Berglin L，Sarman S，van der Ploeg I，et al．Reduced choroidal neovascular membrane formation in matrix metalloproteinase－2－deficient mice．Invest Ophthalmol Vis Sci，2003Jan；44（1）：403—408
71 Zhang H，Li C，Baciu PC．Expression of integrins and MMPs during alka－line－burn－induced comeal angiogenesis．Invest Ophthalmol Vis Sci，2002，43（4）：955—962
72 Ma DH，Chen JK，Kim WS．Expression of matrix metalloproteinases 2 and 9and tissue inhibitors of metalloproteinase 1and 2in inflammation induced comeal neovascularization．Ophthalmic Res，2001，33（6）：353—362
73 Chong NH，Kvanta A，Seregard S，et al．TIMP－3mRNA is not overexpressed in Sorsby fundus dystrophy．Am J Ophthalmol．2003，136（5）：954—955
74 Lelongt B，Bengatta S，Delauche M，et al．Matrix metallopfoteinase 9 protects mice from antiglomerular basement membrane nephritis throughits fibrinolytic activity．J Exp Med，2001，193（7）：793—802
75 Puyraimond A．MMP－2colocalizes with caveolae on the surface of en－dothelial cells．Exp Cell Res，2001，262（1）：28—36
76 Silletti S．Disruption of matrix metalloproteinase 2binding to integrin alpha vbeta 3by an organic molecule inhibits angiogenesis and tumor growth in vivo．Pfoc Ncad Acad Sci，2001，98（1）：119—124
77 Galvez BG，Matias－Roman S，Albar JP，et al．Membrane type1－matrix metalloproteinase is activated during migration of human endothelialcells and modulates endothelial motility and matrix remodeling．J Biol Chem， 2001，276（40）：37491—37500
78 SJ，Patterson ML，Butlefr MJ，et al．Membrane type 1matrix metalloproteinase and gelatinase A synergistically degrade type 1collagen in a cell model．FEBS Lett，2001，491（3）：222—226
79 Deryugina EI．Up－regulation of vascular endothelial growth factor by membrane－type 1matrix metalloproteinase stimulates human glioma xenograft growth and angiiogenesis．Cancer Res，2002，62（2）：580—588
80 Kvanta A，Sarman S，Fagerholm P．Expression of matrix metalloproteinase－2and vascular endothelial growth factor（VEGF）in inflammation asso－ciated comeal neovascularization．Exp Eye Res，2000，70（4）：419—428 81 Park HI，Ni J，Gerkema FE，et al．Identification and characterization of human endometase（matrixmetallo proteinase－26）from endometrial tumer．J Biochem，2000，275（27）：20540—20544
82 Sternlicht MD，Werb Z．How matrix metalloproteinases regulate cell behavior．Annu Rev Cell Dev Biol，2001，17：463—516
83 Davis GE，Senger DR．Endothelial extracellular matrix：biosynthesis，remodeling and functions during vascular morphogenesis and neovessel stabilization．Circ Res，2005，97（11）：1093—1097
84 Abraham D，Ponticos M，Nagase H．Connective tissue remodeling：cross－talk between endothelins and matrix metalloproteinases．Curr Vasc Pharmacol，2005，3（4）：369—379
85 Brew K，Dinakarpandian D，Nagase H．Tissue inhibitors of metalloproteinases：evolution，structure and function．Biophys Acta，2000，1477（1－2）：267—283
86 Galis ZS，Khatri JJ．Matrix metalloproteinases in vascular remodeling and atherogenesis：the good，the bad，and the ugly．Circ Res，2002，90：251—262
87 闫训友，薛 冲，刘志敏，等．基质金属蛋白酶及其组织抑制剂研究进展．生物技术通讯，2004，15（3）：302—305
88 张 雷，王康孙．脉络膜新生血管．国外医学·眼科学分册，2003，27（5）：301—305
89 王巧玲，张盟辉．基质金属蛋白酶与角膜新生血管．当代医药卫生，2005，2（8）：33—37
90 陈华江，王杰军．基质金属蛋白酶的结构及其调节机制．国外医学·肿瘤学分册，2001，28（1）：20—23
91 陈明清，李文亮，赵贤宝．基质金属蛋白酶与肿瘤血管形成关系的研究进展，国外医学·肿瘤学分册，2003，30（6）：431—433